Monitoring therapy with a gonadotropin-releasing hormone analog: utility of MR imaging.

Marlene Zawin, M Zawin, S McCarthy, Shirley McCarthy, L Scoutt, Leslie M. Scoutt, R Lange, G Lavy, Gad Lavy, J Vulte, F Comite, Florence Comite
Radiology · 1990 · vol. 175(2) , pp. 503–506 · doi:10.1148/radiology.175.2.2109336 · PMID:2109336 · W1990429782
article OA: closed CC0 ⤵ 16 in-corpus citations
View on OpenAlex View on PubMed View at publisher

Abstract

The utility of magnetic resonance (MR) imaging in assessing response to therapy with a gonadotropin-releasing hormone (GnRH) analog was assessed in 19 women with uterine leiomyomas and 19 women with endometriosis. There was a significant reduction in individual fibroid volumes at 3 months (P less than .05) and at 6 months (P less than .005) in the drug group, whereas there was no significant change in the placebo group. Vessel conspicuity significantly decreased at 3 months (P less than .02) and at 6 months (P less than .01) in the drug group but not in the placebo group. In the patients with endometriosis, there was a significant decrease (P less than .0006) in the number of endometriomas visualized. Significant changes were also noted in the pelvis in women who were receiving the GnRH analog. After 6 months of therapy, the identifiability of the ovaries was significantly poorer (P less than .05). The authors conclude that the utility of conservative therapy with a GnRH analog can be quantitatively assessed with MR imaging.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Antineoplastic Agents Endometriosis Gonadotropin-Releasing Hormone Leiomyoma Magnetic Resonance Imaging Uterine Neoplasms Abdominal Neoplasms Abdominal Neoplasms Abdominal Neoplasms Adult Antineoplastic Agents Endometriosis Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Leiomyoma Leiomyoma Leuprolide

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (16)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:10.587122+00:00
License: CC0 · commercial use OK